Will Exelixis Stock Double Again by 2031? A Comprehensive Q&A
Exelixis (NASDAQ: EXEL) has delivered impressive returns over the past five years, nearly matching the S&P 500's performance. Many analysts believe the biotech firm could repeat this feat and become a "2-bagger" by 2031. In this Q&A, we explore the company's track record, growth drivers, risks, and future potential.
1. How Has Exelixis Stock Performed Recently and What Does "2-Bagger" Mean?
Exelixis stock climbed 101% over the past five years, slightly outperforming the S&P 500. A "2-bagger" is a term used when a stock doubles in value (100% return). Given this historical performance, the company is well-positioned to achieve similar gains again by 2031. Factors include a strong pipeline, strategic partnerships, and a focus on oncology treatments. Read more about the company's growth strategy in Question 3.
2. What Is Exelixis and Its Main Business Focus?
Exelixis is a biopharmaceutical company dedicated to developing and commercializing small-molecule therapies for cancer. Its flagship product, cabozantinib (marketed as Cometriq and Cabometyx), targets various solid tumors. The company also invests in early-stage research and collaborations to expand its oncology portfolio. With a robust pipeline and strong commercial execution, Exelixis has become a key player in the cancer treatment space.
3. What Are the Key Growth Drivers That Could Double the Stock by 2031?
Several factors support the potential for doubling by 2031: expansion of cabozantinib into new indications (e.g., prostate cancer), promising pipeline assets like XL092 and XB-002, strategic partnerships with companies like Ipsen and Takeda that provide revenue and validation, and a strong balance sheet allowing for reinvestment in R&D. Additionally, the growing global oncology market offers a tailwind. See associated risks.
4. What Risks Should Investors Consider Before Betting on Exelixis?
Investing in Exelixis is not without risks. The biotech sector is volatile, and clinical trial failures can severely impact stock prices. Competition from other cancer drugs (e.g., from Merck, Bristol-Myers Squibb) poses a threat. Regulatory challenges and patent expirations on cabozantinib could reduce revenue. Moreover, the company’s reliance on a single blockbuster drug increases concentration risk. Despite a promising outlook, these uncertainties make it important to diversify.
5. How Does Exelixis Compare to the Broader Market (S&P 500)?
Over the past five years, Exelixis stock returned 101%, beating the S&P 500's return (approximately 95% over the same period). However, biotech stocks are generally more volatile. While the S&P 500 offers stability and diversification, Exelixis provides higher upside potential but also greater risk. For long-term investors willing to tolerate swings, a small allocation to Exelixis could enhance portfolio returns, provided due diligence is done.
6. What Is the Outlook for Exelixis's Pipeline Beyond Cabozantinib?
Beyond cabozantinib, Exelixis has several candidates in development. XL092 is a next-generation tyrosine kinase inhibitor showing promise in early trials for multiple cancers. XB-002 targets tissue factor in solid tumors. Additionally, the company is exploring immuno-oncology combinations. Success in these programs could diversify revenue streams and catalyze the stock's next leg up. However, most are still in early stages, so significant value creation may take time.
7. Is Now a Good Time to Buy Exelixis Stock?
Timing the market is challenging, but Exelixis's current valuation (as of early 2025) may offer a reasonable entry point. With a price-to-earnings ratio below the biotech average and solid fundamentals, the stock could appeal to growth investors. However, considering the risks, it's wise to dollar-cost average or wait for dips. The company's strong cash position also supports potential buybacks. Review performance history before making a decision.